See What HealthDay Can Do For You
Contact Us

Zolpidem Use Linked to Motor Vehicle Collisions in Elderly

Significantly higher rates of motor vehicle collisions in women and adults aged ≥80 years


THURSDAY, Feb. 25, 2016 (HealthDay News) -- Zolpidem users, especially women and individuals aged ≥80 years, have higher rates of motor vehicle collisions (MVCs), according to a study published online in Sleep Medicine.

John N. Booth III, from the University of Alabama at Birmingham, and colleagues examined the correlation between current use of zolpidem-containing medications and MVCs in 2,000 drivers aged ≥70 years. The five-year MVC and at-fault MVC rate ratios (RRs) were estimated for zolpidem users versus nonusers.

The researchers found that after adjustment, there was attenuation of the RR of MVCs comparing zolpidem users versus nonusers (unadjusted: 1.46; 95 percent confidence interval [CI], 1.02 to 2.08 versus adjusted: 1.38; 95 percent CI, 0.97 to 1.98). The unadjusted and adjusted RRs were 1.65 (95 percent CI, 1.03 to 2.66) and 1.61 (95 percent CI, 1.00 to 2.60), respectively, for women. Among those aged ≥80 years the unadjusted and adjusted RRs were 2.24 (95 percent CI, 1.19 to 4.57) and 2.35 (95 percent CI, 1.20 to 4.61), respectively. There were no statistically significantly correlations for men or participants aged younger than 80 years. The patterns were similar for at-fault MVCs.

"Practitioners should consider behavioral treatment before initiating low doses of zolpidem and escalating it as needed to achieve restorative sleep in females and individuals aged ≥80 years to reduce the risk of zolpidem-associated MVCs," the authors write.

Full Text (subscription or payment may be required)

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.